Benign prostatic hyperplasia and PSA: the domino effect
After U.S. Preventive Services Task Force published a recommendation against prostate cancer screening, the medical community cannot extricate itself from all specific features associated with the prostate-specific antigen (PSA). The focus given to the guidelines of the Prostatic Hyperplasia happens...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2012 |
| País: | Brasil |
| Institución: | Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
| Repositorio: | Revista Brasileira de Medicina de Família e Comunidade (Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.rbmfc.org.br:article/654 |
| Acceso en línea: | https://rbmfc.org.br/rbmfc/article/view/654 |
| Access Level: | acceso abierto |
| Palabra clave: | Prostatic Hyperplasia Prostate-Specific Antigen Risk Assessment Hiperplasia Prostática Antígeno Prostático Específico Medición De Riesgo Medição de Risco |
| Sumario: | After U.S. Preventive Services Task Force published a recommendation against prostate cancer screening, the medical community cannot extricate itself from all specific features associated with the prostate-specific antigen (PSA). The focus given to the guidelines of the Prostatic Hyperplasia happens for the possible sharing of a certain point of its approach with the prostatic cancer case-finding, that is the PSA test. The results of two large clinical trials represent the largest body of evidence and they say the number of men who avoided prostate cancer death after subjected to screening was reduced. There is evidence that 100-200 in 1000 screened men will have a false-positive, most of which will have a biopsy with possible psychological damage and organic. The GP should remember that it is not recommended to provide this test, without first discussing together with the patient, the issues that are inherent to the PSA sample. |
|---|